Orbit Genomics, founded in 2003, is creating waves in the field of precision healthcare with its theme of ushering in "The Future of Precision Healthcare." This innovative company is based in the United States, focusing on the diagnosis, treatment, and prevention of complex diseases such as cancer, heart disease, and neurological disorders.
The cornerstone of Orbit Genomics's technological innovation is its patented, AI-powered OrbiSeq™ platform. This advanced technology analyzes previously inaccessible genetic variations crucial for disease diagnosis, risk stratification, and intervention strategies. Their leading product, a blood test for early-stage lung cancer diagnosis, is a testament to the company's groundbreaking approach.
Orbit Genomics recently secured a Non Equity Assistance investment from the CancerX Startup Accelerator on February 26, 2024. This support aligns with their ambitious vision in transforming healthcare solutions.